Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 179-188

  Subramanian, Manikandan ^a   Thorp, Edward ^b   Hansson, Goran K ^c   Tabas, Ira ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CD3+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; GENE DELETION; GENE INACTIVATION; HYPERCHOLESTEROLEMIA; INFLAMMATORY CELL; INTRACELLULAR SIGNALING; LYMPHOCYTIC INFILTRATION; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHEMOKINE CCL2; DENDRITIC CELLS; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MONOCYTES; MYELOID DIFFERENTIATION FACTOR 88; RECEPTORS, LDL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873814446     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64617     Document Type: Article

References (60)

1. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3): 204-212.
2. Members WG, et al. Heart Disease and Stroke Statistics - 2012 Update. Circulation. 2012;125(1):e2-e220.
3. Tacke F, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117(1): 185-194.
4. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13: 251-276.
5. Mallat Z, Taleb S, Ait-Oufella H, Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res. 2009;50(suppl):S364-S369.
6. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen- specific immune responses. Proc Natl Acad Sci U S A. 2005;102(5): 1596-1601.
7. Ait-Oufella H, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12(2): 178-180.
8. Butcher MJ, Gjurich BN, Phillips T, Galkina EV. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment /novelty and significance. Circ Res. 2012;110(5): 675-687.
9. Taleb S, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med. 2009;206(10): 2067-2077.
10. Gautier EL, et al. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation. 2009;119(17): 2367-2375.
11. Shaposhnik Z, Wang X, Weinstein M, Bennett BJ, Lusis AJ. Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2007;27(3): 621-627.
12. Sun J, et al. Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation. 2010;122(8): 808-820.
13. MacRitchie N, et al. Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32(11): 2569-2579.
14. Choi J-H, et al. Flt3 Signaling-dependent dendritic cells protect against atherosclerosis. Immunity. 2011;35(5): 819-831.
15. Hermansson A, Johansson DK, Ketelhuth DFJ, Andersson J, Zhou X, Hansson GK. Immunotherapy with tolerogenic apolipoprotein B-100- loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation. 2011;123(10): 1083-1091.
16. Klingenberg R, et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(5): 946-952.
17. Hou B, Reizis B, DeFranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity. 2008;29(2): 272-282.
18. Packard R, Lichtman A, Libby P. Innate and adaptive immunity in atherosclerosis. Semin Immunopathol. 2009;31(1): 5-22.
19. Koltsova EK, et al. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest. 2012;122(9): 3114-3126.
20. Paulson KE, Zhu S-N, Chen M, Nurmohamed S, Jongstra-Bilen J, Cybulsky MI. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ Res. 2010;106(2): 383-390.
21. Liu P, et al. CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol. 2008;28(2): 243-250.
22. Weber C, et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest. 2011;121(7): 2898-2910.
23. Potteaux S, et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest. 2011;121(5): 2025-2036.
24. Saederup N, Chan L, Lira SA, Charo IF. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2?/? mice. Circulation. 2008;117(13): 1642-1648.
25. Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5): 636-645.
26. Stephens LA, Gray D, Anderton SM. CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci U S A. 2005;102(48): 17418-17423.
27. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol. 2003;170(8): 3939-3943.
28. Kitamura M. Identification of an inhibitor targeting macrophage production of monocyte chemoattractant protein-1 as TGF-beta 1. J Immunol. 1997;159(3): 1404-1411.
29. Feinberg MW, et al. Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res. 2004;94(5): 601-608.
30. ten Dijke P, Arthur HM. Extracellular control of TGF[beta] signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8(11): 857-869.
31. Ménoret A, Myers LM, Lee S-J, Mittler RS, Rossi RJ, Vella AT. TGFβ?protein processing and activity through TCR triggering of primary CD8+ T regulatory cells. J Immunol. 2006;177(9): 6091-6097.
32. Yilmaz A, et al. Emergence of dendritic cells in rupture- prone regions of vulnerable carotid plaques. Atherosclerosis. 2004;176(1): 101-110.
33. Bobryshev YV, Lord RS. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of vascular dendritic cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol. 1995;58(3): 307-322.
34. Bobryshev YV, Lord RS. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res. 1995;29(5): 689-696.
35. Jongstra-Bilen J, Haidari M, Zhu S-N, Chen M, Guha D, Cybulsky MI. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med. 2006;203(9): 2073-2083.
36. Luchtefeld M, et al. Chemokine receptor 7 knockout attenuates atherosclerotic plaque development. Circulation. 2010;122(16): 1621-1628.
37. Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol. 2002;23(8): 403-408.
38. Bjorkbacka H, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004;10(4): 416-421.
39. Michelsen KS, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004;101(29): 10679-10684.
40. van den Berg TK, Kraal G. A function for the macrophage F4/80 molecule in tolerance induction. Trends Immunol. 2005;26(10): 506-509.
41. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol. 2010; 10(6): 453-460.
42. Cho HJ, et al. Induction of dendritic cell-like phenotype in macrophages during foam cell formation. Physiol Genomics. 2007;29(2): 149-160.
43. Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of Apoe?/? mice. Arterioscler Thromb Vasc Biol. 2008;28(8): 1421-1428.
44. Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol. 2007;178(9): 5635-5642.
45. van Puijvelde GHM, et al. Induction of oral rolerance to HSP60 or an HSP60-Peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(12): 2677-2683.
46. Yang K, Li D, Luo M, Hu Y. Generation of HSP60-specific regulatory T cell and effect on atherosclerosis. Cell Immunol. 2006;243(2): 90-95.
47. Gotsman I, et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation. 2006;114(19): 2047-2055.
48. Li H, Ding Y, Yi G, Zeng Q, Yang W. Establishment of nasal tolerance to heat shock protein-60 alleviates atherosclerosis by inducing TGF-β-dependent regulatory T cells. J Huazhong Univ Sci Technolog Med Sci. 2012;32(1): 24-30.
49. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21(10): 1105-1111.
50. Takahashi T, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10(12): 1969-1980.
51. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive Foxp3+ regulatory T cells: more of the same or a division of labor? Immunity. 2009;30(5): 626-635.
52. Gotsman I, Gupta R, Lichtman AH. The influence of the regulatory T lymphocytes on atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(12): 2493-2495.
53. Maganto-García E, et al. Foxp3+-inducible regulatory t cells suppress endothelial activation and leukocyte recruitment. J Immunol. 2011;187(7): 3521-3529.
54. Lievens D, et al. Abrogated transforming growth factor beta receptor II (TGFßRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis [published online ahead of print May 21, 2012]. Eur Heart J. doi:10.1093/eurheartj/ehs106.
55. Mallat Z, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85(8):e17-e24.
56. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(8 suppl):C13-C18.
57. Mallat Z, et al. Inhibition of transforming growth factor-β? signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89(10): 930-934.
58. Habets KL, et al. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res. 2010;85(3): 622-630.
59. Hansson G, Nilsson J. Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin Immunopathol. 2009;31(1): 95-101.
60. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med. 2006;203(5): 1273-1282.